CP-x Synthetic Cannabinoids Cannabinoid Research

CP-x Synthetic Cannabinoids Research Dashboard

26

Primary Studies

18

Related Studies

44

Total Studies

Clinical Studies

2

Double-blind human trials

1

Clinical human trials

Pre-Clinical Studies

1

Meta-analyses/Reviews

13

Animal studies

8

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 44 studies associated with CP-x Synthetic Cannabinoids.

Here is a small sampling of CP-x Synthetic Cannabinoids studies by title:


Components of the CP-x Synthetic Cannabinoids Research Dashboard

  • Top medical conditions associated with CP-x Synthetic Cannabinoids
  • Proven effects in clinical trials for CP-x Synthetic Cannabinoids
  • Receptors associated with CP-x Synthetic Cannabinoids
  • Individual study details for CP-x Synthetic Cannabinoids

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - CP-x Synthetic Cannabinoids

Description of CP-x Synthetic Cannabinoids

The CP class of synthetic cannabinoids are named after the company Carl Pfizer where they were first synthesized. For instance, CP-55,940 was discovered in 1974.

Other Names:

CP Family Synthetic Cannabinoids Levonantradol

CP-x Synthetic Cannabinoids Properties and Effects

Binds with PPAR-Gamma and initiates anti-inflammatory response, Binds with GPR55

CP-x Synthetic Cannabinoids Receptor Binding

Strong affinity for CB1 with a mean Kd at 2.5nM (10 times more potent than THC). Very strong affinity for CB2 with a mean Kd at 0.92nM (38 times more potent than THC)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.